IVIg · Qivigy Kthm, CSL-787

What is IVIg?

IVIg is an immune globulin intravenous product made of human IgG antibodies, supplying a broad spectrum of opsonizing and neutralizing IgG against bacterial and viral agents. The mechanism of action in primary immunodeficiency has not been fully elucidated. It is studied in multifocal motor neuropathy and chronic inflammatory demyelinating polyneuropathy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Qivigy Kthm, CSL-787, CSL787 NEBULIZED IG

Drug type

Plasma-derived product

Therapy area

Immunology, Neurology

Developer

Kedrion S.P.A.

In trials of

ANNX, ARGX

FDA status

Approved as Qivigy Kthm, BLA125822 · FDA label

UNII

66Y330CJHS

✅ FDA-approved uses

• Primary Humoral Immunodeficiency

From the indications section of the FDA label (version of Feb 2, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Inflammatory Demyelinating PolyneuropathyCIDPCIDP - Chronic Inflammatory Demyelinating PolyneuropathyMMNMultifocal Motor Neuropathy (MMN)Safety and Tolerability in Healthy Volunteers

Sources

• FDA label (DailyMed)
• FDA label Qivigy Kthm (2026-02-02), indications
• ClinicalTrials.gov NCT03010046
• ClinicalTrials.gov NCT06742190

Updated Oct 11, 2026.